# PSMA PET Combined With MRI for the Detection of PCa

> **NCT07052214** · PHASE3 · RECRUITING · sponsor: **Telix Pharmaceuticals (Innovations) Pty Limited** · enrollment: 204 (estimated)

## Conditions studied

- PCA
- Prostate Cancer
- Prostatic Neoplasm
- PSMA PET
- Diagnostic Imaging
- Elevated PSA
- Positron Emission Tomography
- Prostate Biopsy
- Carcinoma of the Prostate

## Interventions

- **DRUG:** 68Ga-PSMA-11

## Key facts

- **NCT ID:** NCT07052214
- **Lead sponsor:** Telix Pharmaceuticals (Innovations) Pty Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-18
- **Primary completion:** 2026-06
- **Final completion:** 2026-11
- **Target enrollment:** 204 (ESTIMATED)
- **Last updated:** 2025-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07052214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07052214, "PSMA PET Combined With MRI for the Detection of PCa". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07052214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*